These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 3259905

  • 1. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Cancer Res; 1988 Jul 01; 48(13):3607-12. PubMed ID: 3259905
    [Abstract] [Full Text] [Related]

  • 2. Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Cancer Res; 1987 Jan 01; 47(1):62-9. PubMed ID: 3791221
    [Abstract] [Full Text] [Related]

  • 3. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy.
    Russell SM, Krauer KG, McKenzie IF, Pietersz GA.
    Cancer Res; 1990 Sep 15; 50(18):6028-33. PubMed ID: 2393867
    [Abstract] [Full Text] [Related]

  • 4. Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs.
    Rowland AJ, McKenzie IF, Pietersz GA.
    J Drug Target; 1994 Sep 15; 2(2):113-21. PubMed ID: 8069589
    [Abstract] [Full Text] [Related]

  • 5. In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody.
    Pietersz GA, Toohey B, McKenzie IF.
    J Drug Target; 1998 Sep 15; 5(2):109-20. PubMed ID: 9588867
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts.
    Krauer KG, McKenzie IF, Pietersz GA.
    Cancer Res; 1992 Jan 01; 52(1):132-7. PubMed ID: 1530766
    [Abstract] [Full Text] [Related]

  • 7. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha.
    Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D.
    Cancer Res; 2003 Jun 15; 63(12):3202-10. PubMed ID: 12810649
    [Abstract] [Full Text] [Related]

  • 8. Role of tissue factor in the antitumor effect of recombinant human tumor necrosis factor-alpha in mice.
    Nishigaki F, Miyayasu K, Tsujimoto S, Manda T, Shimomura K.
    Anticancer Res; 1994 Jun 15; 14(6B):2573-6. PubMed ID: 7872683
    [Abstract] [Full Text] [Related]

  • 9. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T, Shimomura K, Mukumoto S, Kobayashi K, Mizota T, Hirai O, Matsumoto S, Oku T, Nishigaki F, Mori J.
    Cancer Res; 1987 Jul 15; 47(14):3707-11. PubMed ID: 3594435
    [Abstract] [Full Text] [Related]

  • 10. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity.
    Palladino MA, Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, Crase D, Marafino B, Aggarwal BB, Figari IS.
    J Immunol; 1987 Jun 01; 138(11):4023-32. PubMed ID: 3295044
    [Abstract] [Full Text] [Related]

  • 11. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates.
    Smyth MJ, Pietersz GA, McKenzie IF.
    J Natl Cancer Inst; 1987 Dec 01; 79(6):1367-73. PubMed ID: 2891866
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo.
    Gatanaga T, Noguchi K, Tanabe Y, Inagawa H, Soma G, Mizuno D.
    J Biol Response Mod; 1989 Jun 01; 8(3):278-86. PubMed ID: 2746298
    [Abstract] [Full Text] [Related]

  • 13. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates.
    Pietersz GA, Smyth MJ, McKenzie IF.
    Cancer Res; 1988 Feb 15; 48(4):926-31. PubMed ID: 3422182
    [Abstract] [Full Text] [Related]

  • 14. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system.
    Furrer M, Altermatt HJ, Ris HB, Althaus U, Rüegg C, Liénard D, Lejeune FJ.
    Melanoma Res; 1997 Aug 15; 7 Suppl 2():S43-9. PubMed ID: 9578416
    [Abstract] [Full Text] [Related]

  • 15. [Monoclonal antibody against brain derived neurotrophic factor inhibits myeloma growth and angiogenesis in the xenograft NOD/SCID animal model].
    Wang YD, Hu Y, Zhang L, Huang J, Sun CY.
    Zhonghua Xue Ye Xue Za Zhi; 2007 Oct 15; 28(10):659-63. PubMed ID: 18399169
    [Abstract] [Full Text] [Related]

  • 16. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B, Siegel SE, Kaiser HE.
    Anticancer Res; 1996 Oct 15; 16(2):661-74. PubMed ID: 8687112
    [Abstract] [Full Text] [Related]

  • 17. In vivo studies of whole ricin monoclonal antibody immunoconjugates for the treatment of murine tumours.
    Kanellos J, MacKenzie IF, Pietersz GA.
    Immunol Cell Biol; 1988 Oct 15; 66 ( Pt 5-6)():403-15. PubMed ID: 3265693
    [Abstract] [Full Text] [Related]

  • 18. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan 15; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK, Mulé JJ, Merino MJ, Rosenberg SA.
    Cancer Res; 1988 Jul 15; 48(14):4011-7. PubMed ID: 3260130
    [Abstract] [Full Text] [Related]

  • 20. TNF induces endogenous TNF in vivo: the basis of EET therapy as a combination of rTNF together with endogenous TNF.
    Inagawa H, Oshima H, Soma G, Mizuno D.
    J Biol Response Mod; 1988 Dec 15; 7(6):596-607. PubMed ID: 3216223
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.